Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to determine wether a rituximab-based treatment compared to standard therapy (glucocorticoid alone) in patients with microscopic polyangiitis without any bad prognosis marker increases the remission and reduces the relapse free survival rate.


Clinical Trial Description

Microscopic polyangiitis (MPA), is a small-sized vessel necrotizing vasculitis associated with anti-neutrophils cytoplasmic antibody (ANCA). Treatment of ANCA associated vasculitis (AAV) was previously based on glucocorticoids (GC) and cyclophosphamide. It has been demonstrated in two prospective randomized trials that rituximab is as effective as cyclophosphamide in the induction treatment of GPA and severe MPA. In addition, it was shown in GPA and MPA that rituximab is superior to azathioprine as maintenance therapy. Patients with MPA without poor prognosis factor (Five factor score (FFS)=0) have not been included in the previous studies and GC alone is considered as the reference treatment in these patients. However, as much as 50% of these patients experience relapses after a 24 months follow-up and only 40% of patients have a long lasting remission. In the group of patients with MPA without any poor prognosis factor (FFS=0), an additional treatment with rituximab might decrease the relapse rate from 40% to 15% after an 18 months' follow-up. The efficacy and safety of this proposal must be tested. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03920722
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Active, not recruiting
Phase Phase 3
Start date October 24, 2020
Completion date September 2023

See also
  Status Clinical Trial Phase
Terminated NCT03712345 - Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA Phase 2
Recruiting NCT02593565 - Vasculitis Pregnancy Registry
Completed NCT03919825 - Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS) - Glucocorticoids Phase 3
Completed NCT00987389 - Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Phase 3
Completed NCT02507024 - The ANCA Vasculitis Questionnaire (AAV-PRO©) N/A
Recruiting NCT03004326 - Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Completed NCT03895801 - Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Phase 2